Somatostatin receptor-targeted radionuclide therapy for progressive meningioma benefit linked to 68Ga-DOTATATE/-TOC uptake
Standard
Somatostatin receptor-targeted radionuclide therapy for progressive meningioma benefit linked to 68Ga-DOTATATE/-TOC uptake. / Seystahl, Katharina; Stoecklein, Veit M; Schüller, Ulrich; Rushing, Elisabeth; Nicolas, Guillaume; Schäfer, Niklaus; Ilhan, Harun; Pangalu, Athina; Weller, Michael; Tonn, Jörg-Christian; Sommerauer, Michael; Albert, Nathalie L.
In: NEURO-ONCOLOGY, Vol. 18, No. 11, 11.2016, p. 1538-1547.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Somatostatin receptor-targeted radionuclide therapy for progressive meningioma benefit linked to 68Ga-DOTATATE/-TOC uptake
AU - Seystahl, Katharina
AU - Stoecklein, Veit M
AU - Schüller, Ulrich
AU - Rushing, Elisabeth
AU - Nicolas, Guillaume
AU - Schäfer, Niklaus
AU - Ilhan, Harun
AU - Pangalu, Athina
AU - Weller, Michael
AU - Tonn, Jörg-Christian
AU - Sommerauer, Michael
AU - Albert, Nathalie L
N1 - © The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
PY - 2016/11
Y1 - 2016/11
N2 - BACKGROUND: The prognosis of patients with progressive meningioma after failure of surgery and radiotherapy is poor.METHODS: We retrospectively evaluated the safety and efficacy of somatostatin-receptor (SSTR)-targeted radionuclide therapy ((177)Lu-DOTATATE [n = 16], (90)Y-DOTATOC [n = 3], or both [n = 1]) in patients with progressive, treatment-refractory meningiomas (5 World Health Organization [WHO] grade I, 7 WHO grade II, 8 WHO grade III) and in part multifocal disease (17 of 20 patients).RESULTS: SSTR radionuclide treatment (median of 3 treatment cycles, median administered dose/cycle 7400 MBq) led to a disease stabilization in 10 of 20 patients for a median time of 17 months. Stratification according to WHO grade showed a median progression-free survival (PFS) of 32.2 months for grade I tumors, 7.2 for grade II, and 2.1 for grade III. PFS at 6 months was 100% for grade I, 57% for grade II, and 0% for grade III. Median overall survival was 17.2 months in WHO grade III patients and not reached for WHO I and II at a median follow-up of 20 months. In the analysis of single meningioma lesions, maximal and mean standardized uptake values in pretherapeutic (68)Ga-DOTATOC/-TATE PET/CT were significantly higher in those lesions with radiographic stability after 6 months. In line with this, high expression of SSTR via immunohistochemistry was associated with PFS >6 months.CONCLUSIONS: SSTR-targeted radionuclide treatment has activity in a subset of patients with meningioma. Expression of SSTR via immunohistochemistry or radionuclide uptake might serve as a predictive biomarker for outcome to facilitate individualized treatment optimization in patients with uni- and multifocal meningiomas.
AB - BACKGROUND: The prognosis of patients with progressive meningioma after failure of surgery and radiotherapy is poor.METHODS: We retrospectively evaluated the safety and efficacy of somatostatin-receptor (SSTR)-targeted radionuclide therapy ((177)Lu-DOTATATE [n = 16], (90)Y-DOTATOC [n = 3], or both [n = 1]) in patients with progressive, treatment-refractory meningiomas (5 World Health Organization [WHO] grade I, 7 WHO grade II, 8 WHO grade III) and in part multifocal disease (17 of 20 patients).RESULTS: SSTR radionuclide treatment (median of 3 treatment cycles, median administered dose/cycle 7400 MBq) led to a disease stabilization in 10 of 20 patients for a median time of 17 months. Stratification according to WHO grade showed a median progression-free survival (PFS) of 32.2 months for grade I tumors, 7.2 for grade II, and 2.1 for grade III. PFS at 6 months was 100% for grade I, 57% for grade II, and 0% for grade III. Median overall survival was 17.2 months in WHO grade III patients and not reached for WHO I and II at a median follow-up of 20 months. In the analysis of single meningioma lesions, maximal and mean standardized uptake values in pretherapeutic (68)Ga-DOTATOC/-TATE PET/CT were significantly higher in those lesions with radiographic stability after 6 months. In line with this, high expression of SSTR via immunohistochemistry was associated with PFS >6 months.CONCLUSIONS: SSTR-targeted radionuclide treatment has activity in a subset of patients with meningioma. Expression of SSTR via immunohistochemistry or radionuclide uptake might serve as a predictive biomarker for outcome to facilitate individualized treatment optimization in patients with uni- and multifocal meningiomas.
KW - Journal Article
U2 - 10.1093/neuonc/now060
DO - 10.1093/neuonc/now060
M3 - SCORING: Journal article
C2 - 27106404
VL - 18
SP - 1538
EP - 1547
JO - NEURO-ONCOLOGY
JF - NEURO-ONCOLOGY
SN - 1522-8517
IS - 11
ER -
